What PTC Therapeutics, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 27 | 206 |
| Total trades | 34 | 298 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 77,078 | 2,564,945 |
| Disposed | 122,370 | 2,577,971 |
| Net activity | −45,292 | −13,026 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Schmertzler Michael | Director | Oct 14 | Open-market sale · S | −382 | $60.14 | −$23K | 1,291,594 |
| Schmertzler Michael | Director | Oct 14 | Open-market sale · S | −2,118 | $59.52 | −$126K | 1,291,976 |
| Boulding Mark Elliott | EXEC. VP AND CLO | Oct 09 | Open-market sale · S | −192 | $64.26 | −$12.3K | 105,272 |
| Boulding Mark Elliott | EXEC. VP AND CLO | Oct 09 | Exercise / conversion · M | +192 | $39.42 | +$7.57K | 105,464 |
| Schmertzler Michael | Director | Oct 07 | Open-market sale · S | −53 | $63.95 | −$3.39K | 1,294,094 |
| Schmertzler Michael | Director | Oct 07 | Open-market sale · S | −2,447 | $63.38 | −$155K | 1,294,147 |
| Boulding Mark Elliott | EXEC. VP AND CLO | Oct 06 | Open-market sale · S | −435 | $64.16 | −$27.9K | 105,272 |
| Boulding Mark Elliott | EXEC. VP AND CLO | Oct 06 | Exercise / conversion · M | +435 | $39.42 | +$17.1K | 105,707 |
| Boulding Mark Elliott | EXEC. VP AND CLO | Oct 05 | Open-market sale · S | −1,638 | $64.03 | −$105K | 105,272 |
| Boulding Mark Elliott | EXEC. VP AND CLO | Oct 05 | Exercise / conversion · M | +1,638 | $39.42 | +$64.6K | 106,910 |
| Steele Glenn Jr Md | Director | Sep 30 | Open-market sale · S | −12,000 | $65.16 | −$782K | 22,500 |
| Steele Glenn Jr Md | Director | Sep 30 | Exercise / conversion · M | +12,000 | $11.23 | +$135K | 34,500 |
| Schmertzler Michael | Director | Sep 17 | Open-market sale · S | −376 | $68.45 | −$25.7K | 1,296,594 |
| Schmertzler Michael | Director | Sep 17 | Open-market sale · S | −9,624 | $67.83 | −$653K | 1,296,970 |
| Schmertzler Michael | Director | Sep 16 | Open-market sale · S | −7,006 | $67.35 | −$472K | 1,306,594 |
| Schmertzler Michael | Director | Sep 16 | Open-market sale · S | −2,994 | $66.58 | −$199K | 1,313,600 |
| Schmertzler Michael | Director | Sep 10 | Open-market sale · S | −10,000 | $67.34 | −$673K | 1,316,594 |
| Schmertzler Michael | Director | Sep 09 | Open-market sale · S | −572 | $68.67 | −$39.3K | 1,326,594 |
| Schmertzler Michael | Director | Sep 09 | Open-market sale · S | −9,428 | $67.79 | −$639K | 1,327,166 |
| Schmertzler Michael | Director | Aug 27 | Open-market sale · S | −610 | $72.22 | −$44.1K | 1,336,594 |
Loading...